Otsu, Japan

Tsutomu Ushijima

This inventor holds 1 USPTO granted patent. Top assignee: Nitto Pharmaceutical Industries, Ltd.. Active years: 2000.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2000

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Tsutomu Ushijima: Innovator in Medical Treatment

Introduction

Tsutomu Ushijima is a notable inventor based in Otsu, Japan. He has made significant contributions to the field of medical treatment, particularly in addressing infections caused by enteropathogenic Escherichia coli. His innovative approach has the potential to improve patient outcomes and enhance therapeutic strategies.

Latest Patents

Ushijima holds a patent for a method aimed at inhibiting the production of toxins from enteropathogenic bacteria. This patent describes a method of treating humans infected with enteropathogenic Escherichia coli by administering butyric-acid bacteria alongside an antibiotic, such as fosfomycin. This innovative treatment method showcases his commitment to advancing medical science.

Career Highlights

Tsutomu Ushijima is associated with Nitto Pharmaceutical Industries, Ltd., where he applies his expertise in developing effective medical solutions. His work has been instrumental in addressing critical health issues, and he continues to contribute to the pharmaceutical industry through his research and innovations.

Collaborations

Ushijima collaborates with Yuiko Matsubara, a fellow researcher, to further enhance the effectiveness of their medical treatments. Their partnership exemplifies the importance of teamwork in the pursuit of scientific advancements.

Conclusion

Tsutomu Ushijima's contributions to medical treatment through his innovative patent highlight his role as a significant inventor in the field. His work not only addresses pressing health concerns but also paves the way for future advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…